GlassScriptPhysician profile
Gloria E Westney
NPI 1104826650
$2,811.95
in general payments reported to CMS, 2019-2025
18 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $368 · 2021: $549 · 2022: $347 · 2023: $52.70 · 2024: $312 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.07 |
| Education | $105.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $470.41 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $325.20 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Advanced Respiratory, INC | $300.00 | 2020 | |
| Ani Pharmaceuticals, INC. | $277.96 | 2024-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.09 | 2019-2025 | |
| Pfizer INC. | $216.30 | 2019-2022 | |
| Abbvie INC. | $191.15 | 2021-2023 | Teflaro |
| United Therapeutics Corporation | $157.02 | 2025 | Tyvaso |
| Olympus America INC. | $146.79 | 2025 | Spiration Valve System |
| Genentech USA, INC. | $99.99 | 2019 | |
| Insmed, INC. | $76.05 | 2025 | Arikayce |
| Philips North America LLC | $68.14 | 2022 | |
| Merck Sharp & Dohme LLC | $63.80 | 2025 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $55.23 | 2025 | Dupixent, Libtayo |
| Glaxosmithkline, LLC. | $41.72 | 2019-2025 | Arexvy, Shingrix, Penmenvy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vapotherm INC | $29.20 | 2021 | |
| Allergan, INC. | $25.54 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $18.36 | 2023 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Westney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.